Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response
Small Methods · 2025
DOI: 10.1002/smtd.202400633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, 2025. Verfasst von Riddha Das und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Nanoparticles, RNA, Messenger, Immunotherapy, Adoptive. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, CSB Development Fund, Karin Grunebaum Cancer Research Foundation.
Abstract (Originalsprache)
Lipid nanoparticles encapsulating mRNA (LNP‐mRNA) revolutionized medicine over the past several years. While clinically approved indications currently focus on infectious disease vaccination, LNP‐mRNA based treatments also hold promise for cancer immunotherapy. However, the route of dosing may impact treatment efficacy, safety, and dose. To minimize adverse effects, it is hypothesized that LNP‐mRNA can be used to activate and engineer dendritic cells (DC) ex vivo before re‐administration of these cells. Here, it is shown that LNP‐mRNA engineered DCs can indeed vaccinate recipient mice. Vaccinated mice showed strong anti‐tumor T cell responses, rejected tumor challenge, and displayed no evidence of toxicity. Further, it is found that DC specific ablation of the immune activating kinase NFkB inducing kinase (NIK) abrogated vaccination efficacy, demonstrating that adoptively transferred DCs can be functionally modified in addition to their antigen presentation capacity. Collectively, these studies show that ex vivo LNP‐mRNA engineering of DCs is a feasible and robust therapeutic strategy for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA, 02114, USA.
- Master's Program in Immunology, Harvard Medical School, 200 Longwood Ave, Boston, MA, 02115, USA.
- Department of Systems Biology, Harvard Medical School, 200 Longwood Ave, Boston, MA, 02115, USA.
- Department of Radiology, Massachusetts General Brigham, 32 Fruit St, Boston, MA, 02114, USA.
- Department of Pathology, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.
ORCID-Profile: Riddha Das, Xinying Ge, Fan Fei, Sepideh Parvanian, Ralph Weissleder, Christopher S Garris
Förderung
- NCI NIH HHS
- CSB Development Fund
- Karin Grunebaum Cancer Research Foundation
- National Cancer Institute
Zitieren
APA
Das, R., Ge, X., Fei, F., Parvanian, S., Weissleder, R., & Garris, C. S. (2025). Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response. Small Methods. https://doi.org/10.1002/smtd.202400633
Vancouver
Das R, Ge X, Fei F, Parvanian S, Weissleder R, Garris CS. Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response. Small Methods. 2025. doi:10.1002/smtd.202400633
BibTeX
@article{Das2025,
author = {Das, Riddha and Ge, Xinying and Fei, Fan and Parvanian, Sepideh and Weissleder, Ralph and Garris, Christopher S},
title = {Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response},
journal = {Small Methods},
year = {2025},
doi = {10.1002/smtd.202400633}
}
EUVIMED